Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse

Background Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown. Methods UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined. Results A total of 113 patients were enrolled, and 48 [42%] relapsed. Fcal ≥ 75 μg/g and FIT ≥ 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively, according to the receiver operating characteristic curves. Both Fcal-positive and FIT-positive statuses were independent predictive factors of clinical relapse (hazard ratio [HR] 2.29; 95% confidence interval [CI], 1.23-4.49; p = 0.0086, and HR 2.91; 95% CI, 1.49-5.50; p = 0.0022, respectively). Categorisation of patients into three groups according to the faecal marker status [FIT-positive, FIT-negative and Fcal-positive, and both negative] can efficiently stratify the risk of relapse with graded increases in risk [FIT-negative and Fcal-positive: HR 2.05; 95% CI, 1.02-4.43; p = 0.0045, and FIT-positive: HR 5.43; 95% CI, 2.57-11.76; p < 0.0001, compared with both negative]. Conclusions Fcal vs FIT showed distinct properties regarding the prediction of relapse in UC. A risk assessment using both faecal markers could increase the predictability for relapse.

[1]  D. Rubin,et al.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Jun Kato,et al.  Consecutive Measurements by Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Detect Clinical Relapse. , 2016, Journal of Crohn's & colitis.

[3]  M. Saruta,et al.  Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis , 2016, Journal of gastroenterology and hepatology.

[4]  Jun Kato,et al.  Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? , 2016, Intestinal research.

[5]  B. Warren,et al.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up , 2015, Gut.

[6]  M. Silverberg,et al.  Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease , 2015, Inflammatory bowel diseases.

[7]  Hiroyuki Okada,et al.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. , 2015, World journal of gastroenterology.

[8]  Jun Kato,et al.  Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test , 2015, The American Journal of Gastroenterology.

[9]  Jun Kato,et al.  Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. , 2014, World journal of gastroenterology.

[10]  P. Siersema,et al.  Fecal Hemoglobin and Calprotectin Are Equally Effective in Identifying Patients with Inflammatory Bowel Disease with Active Endoscopic Inflammation , 2014, Inflammatory bowel diseases.

[11]  K. Yokoyama,et al.  Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis , 2013, Gastroenterology research and practice.

[12]  T. Lobaton,et al.  A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[13]  E. Cotte,et al.  Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases , 2013, Inflammatory bowel diseases.

[14]  L. Öhman,et al.  Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[15]  Jun Kato,et al.  Evaluation of Mucosal Healing of Ulcerative Colitis by a Quantitative Fecal Immunochemical Test , 2013, The American Journal of Gastroenterology.

[16]  S. Vermeire,et al.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[17]  P. Rutgeerts,et al.  Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing , 2012, The American Journal of Gastroenterology.

[18]  D. Franchimont,et al.  Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.

[19]  J. Gisbert,et al.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? , 2010, Journal of Crohn's & colitis.

[20]  P. Renzulli,et al.  Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes , 2009, Inflammatory bowel diseases.

[21]  J. Mate,et al.  P039 - Faecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009 .

[22]  R. D'Incà,et al.  Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.

[23]  D. Martines,et al.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease , 2007, International Journal of Colorectal Disease.

[24]  T. Morikawa,et al.  A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic Population , 2005 .

[25]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[26]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[27]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[28]  J. E. Domínguez-Muñoz,et al.  Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. , 2016, Journal of Crohn's & colitis.

[29]  D. Franchimont,et al.  Results from the 2 nd Scientific Workshop of the ECCO ( I ) : Impact of mucosal healing on the course of inflammatory bowel disease , 2011 .

[30]  T. Morikawa,et al.  A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. , 2005, Gastroenterology.